Business Context and Reporting Period
This Form 8-K was filed by GRI Bio, Inc. on July 2, 2024, with the report date of July 8, 2024. The filing addresses the Company's compliance status with The Nasdaq Stock Market LLC listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status.
Material Changes
- Resolution of Listing Deficiency: The Company received notification from Nasdaq that the equity deficiency under Listing Rule 5550(b) has been cured.
- Compliance Status: GRI Bio, Inc. is now in compliance with all applicable continued listing standards.
- Procedural Update: The Company will no longer appear before the Nasdaq Hearings Panel regarding the prior deficiency reported in November 2023 and May 2024.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or new risk factors. The primary event is the removal of a specific regulatory risk related to delisting.
Investor Verification Checklist
- Verify the specific actions taken by the Company to cure the equity deficiency under Listing Rule 5550(b).
- Review the attached Press Release (Exhibit 99.1) for any additional details on the compliance restoration.
- Confirm the Company's current stock price and market capitalization to ensure continued compliance with Nasdaq minimum bid price and market value requirements.